Standardization as situation-specific achievement: Regulatory diversity and the production of value in intercontinental collaborations in stem cell medicine

Social Science and Medicine

Volumn 122, Issue , 2014, Pages 72-80

  Rosemann, Achim ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

China; Clinical trials; International collaborations; Regenerative stem cell medicine; Research regulation; Scientific self governance; Situational standardization

Indexed keywords

HEALTH SERVICES; STANDARDIZATION;

ARTICLE; CELL REGENERATION; CHINA; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; GOVERNMENT REGULATION; HEALTH CARE NEED; INTERNATIONAL COOPERATION; MEDICAL RESEARCH; PATENT; STANDARDIZATION; STEM CELL TRANSPLANTATION; TREATMENT INDICATION; UNITED STATES; COOPERATION; HUMAN; LEGISLATION AND JURISPRUDENCE; ORGANIZATION AND MANAGEMENT; STANDARDS; STEM CELL;

CHINA;

BIOMEDICAL RESEARCH; COOPERATIVE BEHAVIOR; HUMANS; INTERNATIONAL COOPERATION; STEM CELLS;

EID: 84908337825     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2014.10.018     Document Type: Article

References (38)

1. Barry A. Technological zones. Eur. J. Soc. Theory 2006, 9(2):239-253.
2. Bharadwaj A. Ethics of consensibility, subaltern ethicality: the clinical application of embryonic stem cells in India. BioSocieties 2013, 8(1):25-40.
3. Birch K. Knowledge, place, and power: geographies of value in the bioeconomy. New Genet. Soc. 2012, 31(2):183-201.
4. Boeije H. Apurposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual. Quant. 2002, 36(4):391-409.
5. Brhlikova P., Harper I., Jeffery R., Rawal N., Subedi M., Santhosh M.R. Trust and the regulation of pharmaceuticals: South Asia in a globalised world. Glob. Health 2011, 7(10).
6. Brunsson N., Jacobsson B. AWorld of Standards 2000, Oxford Univ. Press, Oxford.
7. Chen H. Stem cell governance in China: from bench to bedside?. New Genet. Soc. 2009, 28(3):267-282.
8. Chen H., Gottweis H. Stem cell treatments in china: rethinking the patient role in the global bio-economy. Bioethics 2013, 27(4):194-207.
9. Cooper M. Experimental labour-offshoring clinical trials to China. East Asian Sci. Technol. Soc. 2008, 2(1):73-92.
10. Cribb A., Wainwright S., Williams C., Farsides B., Michael M. Towards the applied: the construction of ethical positions in stem cell translational research. Med. Health Care Philos. 2008, 11(3):351-361.
11. Ellis S. Neuralstem doses ischemic stroke patient with stem cells directly into the brain. Neuralstem Website 2014, 5 February, 2014; URL:, (last accessed 10.9.14.). http://neuralstem.com/pharmaceuticals?id=206.
12. Federal Register Human subject protection; foreign clinical studies not conducted under an investigational new drug application. Fed. Regist. 2008, 73(82):22800-22816. URL:, (last accessed 20.4.14.). http://www.gpo.gov/fdsys/pkg/FR-2008-04-28/pdf/E8-9200.pdf.
13. Faulkner A. Law's performativities: shaping the emergence of regenerative medicine through European Union legislation. Soc. Stud. Sci. 2012, 42(5):753-774.
14. Gikonyo C., Bejon P., Marsh V., Molyneux S. Taking social relationships seriously: lessons learned from the informed consent practices of a vaccine trial on the Kenyan Coast. Soc. Sci. Med. 2008, 67:708-720.
15. Halme D.G., Kessler D.A. FDA regulation of stem-cell-based therapies. N.Engl. J. Med. 2006, 355(16):1730-1735.
16. Keating P., Cambrosio A. Cancer on Trial: Oncology as a New Style of Practice 2011, University of Chicago Press.
17. Leach M., Hilton S., Greenwood B.M., Manneh E., Dibba B., Wilkins A., et al. An evaluation of the informed consent procedure used during a trial Haemophilus Influenzae type B conjugate vaccine undertaken in the Gambia, West Africa. Soc. Sci. Med. 1999, 148(2):139-148.
18. Mackey T.K., Liang B.A. The global counterfeit drug trade: patient safety and public health risks. J.Pharm. Sci. 2011, 100(11):4571-4579.
19. Martin P., Brown N., Kraft A. From bedside to bench? Communities of promise, translational research and the making of blood stem cells. Sci. Cult. 2008, 17(1):29-41.
20. McMahon D.S. The global industry for unproven stem cell interventions and stem cell tourism. Tissue Eng. Regen. Med. 2014, 11(1):1-9.
21. Petryna A. When Experiments Travel: Clinical Trials and the Global Search for Human Subjects 2009, Princeton University Press.
22. Rosemann A. Modalities of value, exchange, solidarity: the social life of stem cells in China. New Genet. Soc. 2011, 30(2):181-192.
23. Rosemann A. Medical innovation and national experimental pluralism: insights from clinical stem cell research and applications in China. Biosocieties 2013, 8(1):58-74.
24. Rosemann A. Scientific multipolarisation: its impact on international clinical research collaborations and theoretical implications. Sci. Technol. Soc. 2013, 18(3):339-359.
25. Sariola S., Simpson B. Theorising the 'human subject' in biomedical research: international clinical trials and bioethics discourses in contemporary Sri Lanka. Soc. Sci. Med. 2011, 73(4):515-521.
26. Sleeboom-Faulkner M., Patra P.K. Experimental stem cell therapy: biohierarchies and bionetworking in Japan and India. Soc. Stud. Sci. 2011, 41(5):645-666.
27. Sleeboom-Faulkner M. Latent science collaboration: strategies of bioethical capacity building in Mainland China's stem cell world. BioSocieties 2013, 8(1):7-27.
28. Sleeboom-Faulkner M. Regulation of Cell Research and Therapy International Standardisation and National Home-Keeping 2014, Presentation, China Cell Therapy Conference, June 20, 2014, Shanghai.
29. Smith D.E. Institutional Ethnography: a Sociology for People 2005, Rowman Altamira.
30. Song P. The proliferation of stem cell therapies in post-Mao China: problematizing ethical regulation. New Genet. Soc. 2011, 30(2):141-153.
31. Strathern M. Audit Cultures: Anthropological Studies in Accountability, Ethics and the Academy 2000, Routledge.
32. Timmermans S., Berg M. Standardization in action: achieving local universality through medical protocols. Soc. Stud. Sci. 1997, 27:273-305.
33. Timmermans S., Epstein S. Aworld of standards but not a standard world: toward a sociology of standards and standardization. Annu Rev. Sociol. 2010, 36:69-89.
34. Wahlberg A., Rehmann-Sutter C., Sleeboom-Faulkner M., Lu G., Döring O., Cong Y., et al. From global bioethics to ethical governance of biomedical research collaborations. Soc. Sci. Med. 2013, 98:293-300.
35. Wainwright S.P., Williams C., Michael M., Farsides B., Cribb A. From bench to bedside? Biomedical scientists' expectations of stem cell science as a future therapy for diabetes. Soc. Sci. Med. 2006, 63(8):2052-2064.
36. Webster A., Haddad C., Waldby C. Experimental heterogeneity and standardisation: stem cell products and the clinical trial process. BioSocieties 2011, 6(4):401-419.
37. Wilson-Kovacs D.M., Weber S., Hauskeller C. Stem cells clinical trials for cardiac repair: regulation as practical accomplishment. Sociol. Health Illn. 2010, 32(1):89-105.
38. Young W. SCI: Is the Cure in China? Video of Conference Presentation, Spinal Cord Injury - What Are the Barriers to Cure? 2008, Workshop, Bedford Massachusetts, March 29, 2008, URL:, (last accessed 27.04.14.). http://www.spinalcordworkshop.org/portfolio-type/wise-young-md-phd-spinal-cord-injury-is-the-cure-in-china/.